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Background: Interleukin-37 (IL-37) has been known to play an immunosuppressive role in various inflammatory
disorders, but whether it participates in the regulation of pathogenesis of ankylosing spondylitis (AS) has not been
investigated. Here, we examined the serum levels of IL-37 and its clinical association in AS, and explored the
anti-inflammatory effects of IL-37 on peripheral blood mononuclear cells (PBMCs) from AS patients.
Methods: The mRNA levels of IL-37, TNF-α, IL-6, IL-17, and IL-23 in PBMCs and their serum concentrations from 46
AS patients were examined by real-time polymerase chain reaction (RT-PCR) and enzyme-linked immunoassay (ELISA),
respectively. The correlations between serum IL-37 levels with disease activity, laboratory values and pro-inflammatory
cytokines in AS were analyzed by Spearman correlation test. PBMCs from 46 AS patients were stimulated with
recombinant IL-37 protein, expressions of TNF-α, IL-6, IL-17 and IL-23 were determined by RT-PCR and ELISA.
Results: Compared to healthy controls (HC), AS patients and active AS patients showed higher levels of IL-37
in PBMCs and serum respectively. Strikingly, serum IL-37 levels were higher in AS patients with osteoporosis
than those without. Serum levels of IL-37 were correlated with laboratory values as well as TNF-α, IL-6 and IL-17,
but not IL-23 in patients with AS. The productions of pro-inflammatory cytokines such as TNF-α, IL-6, IL-17, IL-23 in
PBMCs from AS patients were obviously attenuated after recombinant IL-37 stimulation, but not in the HC.
Conclusion: The higher levels of IL-37 were found in AS patients, which were correlated with disease activity and AS
related pro-inflammatory cytokines. More importantly, IL-37 inhibits the expressions of the pro-inflammatory cytokines
from PBMCs in AS patients, indicating the potential anti-inflammatory role of IL-37 in AS.
Keywords: Interleukin-37, Ankylosing spondylitis, Peripheral blood mononuclear cells, Tumor necrosis factor-α,
Interleukin-17, Interleukin-6, Interleukin-23Background
Ankylosing spondylitis (AS) is a prevalent chronic inflam-
matory disease characterized by chronic inflammation in
the axial skeleton and peripheral joints respectively and
leading to bone erosion, which seriously influences the
quality life of patients [1]. Several studies have suggested
that major histocompatibility complex class I (MHC I)
might affect susceptibility to AS, 90-95% of patients with
AS are Human Leukocyte Antigen (HLA) B27 positive* Correspondence: dujing83@hotmail.com; zhuang809@126.com
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unless otherwise stated.[2,3]. The onset, pathogenic process and severity of AS
are depended on the degrees of inflammation in the
disease [4,5].
Although the etiology of AS is unclear, accumulating
evidences have underlined that the levels of pro-
inflammatory cytokines (TNF-α, IL-6, IL-17 and IL-23)
were significantly increased in the peripheral blood of
AS patients [6-12]. Clinical trials suggested that blocking
these cytokines could partly relieve inflammatory symp-
toms of AS and also appears to reduce disease severity
[13-15]. Recent studies have indicated that IL-37 down-
regulated the expressions of pro-inflammatory cytokines
in chronic inflammatory diseases such as system lupus
erythematosus (SLE) [16], rheumatoid arthritis (RA) [17]
and inflammatory bowel disease [18], suggesting IL-37his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to reduce inflammatory responses in AS.
IL-37, belongs to the members of the IL-1 family, has
been described as an anti-inflammatory cytokine in sev-
eral inflammatory diseases [19-21]. IL-37 is highly con-
centrated in the testis, thymus and uterus, and can be
induced in various types of cells such as peripheral blood
mononuclear cells (PBMCs), epithelial cells, dendritic
cells, monocytes and keratinocytes [20-22]. Up-regulated
expressions of IL-37 in serum have been reported in
many inflammation-related disorders, such as systemic
lupus erthymatosus (SLE) [16], rheumatoid arthritis
(RA) [17] and acute coronary syndrome [23]. In vitro,
IL-37 has been demonstrated to effectively abrogate the
expressions of pro-inflammatory cytokines in several cell
types, including PBMCs [20-23]. In vivo, IL-37 reduced
the inflammatory responses and clinical symptoms of
cerebral ischemia, myocardial ischaemia/reperfusion in-
jury, psoriasis, and asthma in mouse models [24-29].
Our published studies showed that IL-37 may play a
negative feedback mechanism to restrain the inflamma-
tory reaction in SLE [16] and Graves’ Disease (GD) [30].
However, the information related to the expression and
function of IL-37 in AS is still lacking.
Here, we investigated the expression of IL-37 in serum
and PBMCs of patients with AS, and correlations ofTable 1 Clinical and laboratory characteristics of the AS patie
Characteristics Active AS (n = 25)
Age in years (mean) 31.2 ± 11.96
Sex, no. Male/no. Female 21/4
HlA-B27, percentage positive (%) 23 (92)
Disease duration (years) 6.3 ± 4.25
Osteoporosis n (%) 18 (72)
Peptic ulcer n (%) 7 (28)
Liver dysfunction n (%) 7 (28)
Intestinal tuberculosis n (%) -
Leukocytosis n (%) 7 (28)
Kidney dysfunction n (%) 4 (16)
Polycythemia n (%) 5 (20)
Hyperlipidemia n (%) 1 (4)
Adult still disease n (%) 1 (4)
CRP in mg/L (median) 15.8 ± 4.51
ESR in mm/h (median) 30.8 ± 14.45
ALT in U/L (median) 28.7 ± 21.19
PLT 109/L (median) 317.4 ± 96.42
RBC in L (median) 5.1 ± 0.56
BASDAI 5.8 ± 0.90
Except where otherwise indicated, values are expressed as mean ± standard deviati
donors in terms of age and sex; BASDAI, (range 0–10); The normal range are 0 ~ 15
for PLT; 9 ~ 50 U/L for ALT; HLA-B27, Human leukocyte atigents-B27; BASDAI, Bath a
erythrocyte sedimentation rate; PLT, Platelet; RBC, red blood cells.serum IL-37 levels with disease activity, complications,
laboratory parameters and pro-inflammatory cytokines
in AS. We further studied the function of IL-37 in AS by




Forty-six AS patients from Peking University Shenzhen
Hospital, Shenzhen, People’s Republic of China were
invited to enroll in our research. All AS patients were in-
dividually diagnosed according to modified New York
Criteria [31]. Thirty-five age-and sex-matched volunteers
were recruited from Peking University Shenzhen Hos-
pital as healthy controls (HC). We excluded other
rheumatic diseases, infections or malignant tumors from
the study. Clinical data from each patient like age, sex,
disease duration, erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP), platelet (PLT) and current medi-
cations were recorded (Table 1). AS disease activity was
identified by Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI) score [32]. BASDAI score ≥ 4 was de-
fined as active AS [33]. The research was approved by the
regional ethics committee in Peking University Shenzhen
Hospital. Written informed consents were obtained from
all participants.nts and controls
Inactive AS (n = 21) AS (n = 46) HCs (n = 35)
28.7 ± 7.52 30.0 ± 10.26 30.3 ± 8.87
13/8 34/12 26/9
18 (86) 5 (89) -
5.6 ± 5.47 6.0 ± 4.76 -
6 (29) 24 (52) -
1 (5) 8 (17) -
10 (48) 17 (37) -
1 (5) 1 (2) -
- 7 (15) -
7 (33) 11 (24) -
3 (14) 8 (17) -
- 1 (2) -
- 1 (2) -
6.2 ± 4.31 11.4 ± 6.56 -
8.3 ± 4.08 20.5 ± 15.87 -
31.4 ± 21.79 30.0 ± 21.50 -
247.6 ± 61.53 285.5 ± 90.49 -
4.9 ± 0.57 5.0 ± 0.57 -
2.9 ± 0.70 4.5 ± 1.66 -
on. There were no significant differences between patients with AS and healthy
mm/h for ESR; 0 ~ 5 mg/L for CRP; 4.0 ~ 5.5 × 1012/L for RBC; 100 ~ 300 × 109/L
nkylosing spondylitis disease activity index; CRP, C-reactive protein; ESR,
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(PBMCs) isolation
Blood samples were obtained by venous blood. PBMCs
were isolated from AS patients and HC using Ficoll-
Paque Plus (TBD science, China) following the manufac-
turer’s instruction under sterile conditions. The collected
cells were used for cell cultures or frozen at −80°C until
RNA extractions. Serum samples were stored at −80°C
until cytokines were determined.Recombinant human IL-37 protein
We have cloned, expressed, and purified human recom-
binant IL-37 protein, and confirmed its functions in our
pervious study [16]. The concentrations of the protein
were detected by Brandford methods, and the recombin-
ant protein was stored at −20°C.Cell culture condition
Whole PBMCs were cultured in RPMI 1640 (Hyclone,
Thermo, USA) with 100 μg/ml streptomycin (Beyotime,
China), 100 IU/ml penicillin and 10% Fetal Calf serum
(Sijiqing, China) as culture medium in a humidified at-
mosphere of 5% CO2 at 37°C. Cells were stimulated with
or without human recombinant IL-37 at various concen-
trations for 6 h, and then incubated further with LPS
(1 μg/ml) for 4 h. Total RNAs were extracted [16], and
cytokine transcriptions were analyzed by RT-PCR. To
determine cytokine protein expressions in PBMCs, cells
were stimulated with or without human recombinant
IL-37 at 100 ng/ml for 24 h, and then incubated fur-
ther with LPS (1 μg/ml) for 8 h, culture supernatants
were harvested and frozen at −80°C for later cytokine
analysis by ELISA.RNA extraction and real-time polymerase chain reaction
(RT-PCR)
Total RNAs were extracted from PBMCs using Trizol
(Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s protocol. The quantity and purity of RNA were
then detected by Epoch 18 multi-volume Spectropho-
tometer System (Biotek, USA) at 260 nm and 280 nm. For
subsequent reverse transcription reaction, samples with
ratios from 1.8 to 2.0 were accepted. cDNAs were ob-
tained using the iScript™ cDNA Synthesis Kit (Thermo,
Pittsburgh PA, USA). RT-PCRs were performed using the
SYBR Green PCR kit (Bio-rad, USA) and a CFX96 Real-
Time PCR system (Bio-rad, USA). PCR products were
amplified in duplicate in a total volume of 20 μL, verified
by melting curve analysis. Relative mRNAs levels of target
genes were calculated with normalization to β-actin values
using the 2-ΔΔct method. The primer sequences were sum-
marized (Table 2).Enzyme-Linked Immunosorbent Assay (ELISA)
Serum IL-37 levels were measured with a commercially
available enzyme-linked immunosorbent assay (ELISA)
kit that specifically detects IL-37 (AdipoGen AG, Liestal,
Switzerland). Detections of the cytokine TNF-α, IL-17,
IL-6 and IL-23 were accomplished by using eBioscience
ELISA Kit (San Diego, CA, USA).
Statistical analysis
Data were expressed as mean (± SEM) analyzed by Graphpad
Prism V.5.00 software (GraphPad Software, San Diego
CA, USA). Differences between two groups were per-
formed with Mann–Whitney U-test for nonparametric
data. Spearman correlation test was used to evaluate the
associations between serum IL-37 levels and laboratory
values as well as serum cytokine levels. For all experi-
ments, P < 0.05 was considered as statistically significant.
Results
Elevated expression of IL-37 mRNA in PBMCs from
patients with AS especially patients with active AS
To investigate the association between IL-37 levels and
AS, IL-37 mRNA expression in PBMCs from AS patients
and healthy controls was detected by RT-PCR. Our results
for the first time revealed that the expressions of IL-37
mRNA in PBMCs from AS patients were higher than
those from HC (Figure 1A). We next analyzed IL-37
mRNA expressions in PBMCs from patients with active
AS and inactive AS and found that a significant up-
regulation of IL-37 mRNA expressions in active AS pa-
tients compared with inactive AS patients and healthy
controls (Figure 1A). No difference was observed in IL-37
mRNA levels between inactive AS patients and healthy
controls (Figure 1A).
IL-37 is elevated in the serum from patients with AS
especially patients with active AS
As shown in Figure 1B, serum IL-37 protein levels were
significantly higher in AS patients compared with HC.
Moreover, we identified a significant elevation of serum
IL-37 levels in active AS patients compared with inactive
AS patients and HC (Figure 1B). There is no difference
in the serum IL-37 levels between patients with inactive
AS and healthy controls (Figure 1B).
Relationships between serum IL-37 levels and disease
activity as well as laboratory indexes in patients with AS
Next, we examined the potential relationship of IL-37
levels with laboratory values including erythrocyte sedi-
mentation rate (ESR), C-reactive protein (CRP) and clin-
ical assessments of disease activity (defined by BASDAI).
The results revealed that serum IL-37 levels were posi-
tively associated with BASDAI (Figure 2A, r = 0.4302, p =
0.0028). Accordingly, serum IL-37 levels have a significantly
Table 2 List of the sequence of human gene primers
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p = 0.0298), and ESR (Figure 2C, r = 0.4649, p = 0.0011),
respectively. But, we did not observe the correlation of
serum IL-37 levels with red blood cell (RBC), alanine ami-
notransferase (ALT) (Table 3).
Associations of serum IL-37 with pro-inflammatory
cytokines levels
Published studies demonstrated that pro-inflammatory
cytokines IL-17, TNF-α, IL-6 and IL-23 play an import-
ant role in promoting disease development of AS [5-11].
Consistent with these findings, we also demonstrated that
the levels of serum IL-17, TNF-α, IL-6 and IL-23 were sig-
nificantly higher in patients with AS than healthy controls
(data not shown).
To assess the potential relationships of serum IL-37
levels and the levels of above mentioned pro-inflammatory
cytokines in patients with AS, the correlations between
IL-37 and IL-6, IL-17, TNF-α, IL-23 were analyzed by
Spearman correlation test. The results indicated that the
concentrations of serum IL-37 levels were positively corre-
lated with the levels of serum IL-6 (Figure 3A, r = 0.4005,
P = 0.0058), IL-17 (Figure 3B, r = 0.4922, p = 0.0005) and
TNF-α (Figure 3C, r = 0.3907, p = 0.0073), respectively.Figure 1 Comparison of IL-37 mRNAs and protein levels between AS
(n = 25) and inactive AS patients (n = 21) and in HC (n = 35) were measured
levels in an active (n = 25) and inactive AS patients (n = 21) and HC (n = 35
patient and HC. Horizontal lines indicate median values. Differences betwe
nonparametric data. AS, ankylosing spondylitis; HC, healthy control; NS,However, no significant correlation was observed between
IL-37 and IL-23 in AS patients (Figure 3D, r = 0.1095,
p = 0.4689).
Correlations between serum IL-37 levels and AS clinical
features
To further evaluate the relationships between serum
IL-37 levels and AS clinical manifestations, the levels of
serum IL-37 were used to compare among patients with
and those without AS definite clinical features. Our data
showed that no significant differences in serum IL-37
levels with peptic ulcer, liver dysfunction, intestinal tuber-
culosis, leukocytosis, kidney dysfunction, polycythemia,
hyperlipidemia and adult still disease in AS patients
(Table 4). Interestingly, the expressions of IL-37 mRNA in
PBMCs (Figure 4A) and the levels of serum IL-37 (Figure 4B)
were significantly higher in patients with osteoporosis
compared with patients without osteoporosis. However,
compared to healthy controls, AS patients without osteo-
porosis did not show significantly higher IL-37 mRNA
(Figure 4A) and protein levels (Figure 4B). We also found
that an elevated IL-37 protein level from active AS
patients with OP than inactive AS patients with OP as
well as HC. Similarly, compared to inactive AS patientsand HC. (A) The expressions of IL-37 mRNA from PBMCs in active
by RT-PCR, results are expressed as mean ± SEM. (B) Serum IL-37
) were measured by ELISA. Each symbol represents an individual AS
en two groups were performed with Mann–Whitney U-test for
not significant; *P < 0.05; **P < 0.01.
Figure 2 Correlations of serum IL-37 levels and laboratory values. Serum IL-37 levels were positively correlated with BASDAI (A), CRP (B),
and ESR (C) respectively. Each symbol represents an individual patient. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index. ESR,
erythrocyte sedimentation rate; CRP, C-reactive protein. The correlations were evaluated with Spearman’s non-parametric test. P < 0.05
represents a significant difference.
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higher IL-37 levels in serum [Additional file 1]. These re-
sults indicated the expressions of IL-37 are closely related
to the AS patients with osteoporosis.
Recombinant IL-37 decreases the productions of
pro-inflammatory cytokines in PBMCs from patients with AS
IL-37 has been reported to play an anti-inflammatory
role in auto-immune and inflammatory disease through
down-regulation of inflammatory response [16-18]. To
investigate whether IL-37 has a similar capacity to de-
crease the expressions of pro-inflammatory cytokines in-
volved in the pathogenesis of AS. First of all, we had
expressed and purified recombinant human IL-37 pro-
tein based on previous methods [16]. To determine the
anti-inflammatory role of IL-37 in AS, the PBMCs iso-
lated from AS patients and HC were cultured in the
presence or absent of recombinant IL-37 and furtherTable 3 Correlation between IL-37 levels and
pro-inflammatory cytokines as well as AS laboratory values











BASDAI, Bath ankylosing spondylitis disease activity index; CRP, C-reactive protein;
ESR, erythrocyte sedimentation rate; ALT, alanine aminotransferase; PLT, Platelet;
RBC, red blood cell. The correlations were evaluated with Spearman’s
non-parametric test. P < 0.05 represents a significant difference.with LPS stimulation. The cells and cultural supernatants
were harvested for ELISA and RT-PCR analysis, respect-
ively. We found that the expressions of pro-inflammatory
cytokines TNF-α (Figure 5A), IL-6 (Figure 5B), IL-23
(Figure 5C) and IL-17 (Figure 5D) mRNA in the PBMCs
of AS patients were dramatically suppressed by IL-37
treatment. Meanwhile, IL-37 also markedly reduced the
secretions of TNF-α (Figure 5E), IL-6 (Figure 5F), IL-23
(Figure 5G) and IL-17 (Figure 5H) in the cultural superna-
tants of the PBMCs in AS patients. Interestingly, the pro-
ductions of these cytokines mRNAs and protein levels of
the PBMCs in HC were unaffected by IL-37 stimulation
(Figure 5A-H).
Discussion
Our previous studies have demonstrated that IL-37 plays
as an immune mediator to restrain the inflammatory re-
sponse of autoimmune diseases in SLE and GD [16,30].
Other published data have shown that IL-37 has a
pivotal function in inflammatory regulation of inflamma-
tory disorders [17,18]. Yet, it is still not clear whether
IL-37 is involved in the pathogenesis of AS. Here, we for
the first time reported that IL-37 concentrations in
serum and IL-37 mRNA expression in PBMCs were
dramatically higher in AS patients compared to HC, and
the levels of IL-37 positively correlated with the disease
activity, especially with the major pro-inflammatory
cytokines related to AS. These data suggested IL-37
closely relates to AS, especially the activity of AS, and
may play an important role in inflammatory regulation
within the AS.
Several complications often present in AS patients,
such as uveitis, inflammatory bowel disease, and psoria-
sis [4]. Osteoporosis (OP) is a common complication in
the pathogenesis of AS and it can raise the risk of bone
fracture [34]. The published data have indicated that
osteoporosis was related to the AS disease activity [35].
Figure 3 Associations between serum levels of IL-37 and pro-inflammatory cytokines in AS patients. Serum IL-37 levels were positively
correlated with IL-6 (A), IL-17 (B), TNF (C) respectively except for IL-23 (D). Each symbol represents an individual patient. The correlations were
evaluated with Spearman’s non-parametric test. P < 0.05 represents a significant difference. NS, not significant.
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common in active AS patients than in inactive AS pa-
tients (Table 1). Pro-inflammatory cytokines have been
shown to be involved in AS disease activity [8,36]. Marina
Magrey et al. revealed that OP was associated with the
high levels of pro-inflammatory cytokines in AS pa-
tients [37]. Indeed, our results confirmed that serum pro-
inflammatory cytokines levels were significantly higher in
AS patients with OP than those without OP. Interestingly,
our experiments also indicated that the levels of serum
IL-37 were significantly higher in AS patients with OP
than those without OP (Figure 4). Furthermore, we ob-
served the positively correlation between the levels ofTable 4 Serum IL-37 protein levels in the presence or absence
Clinical characteristics n Present median (interquartile rang
Osteoporosis 24 239.970 (386.146 to 107.470)
Peptic ulcer 8 236.358 (135.338 to 341.248)
liver dysfunction 17 225.617 (116.759 to 279.320)
Intestinal tuberculosis 1 198.814
Leukocytosis 7 250.126 (169.398 to 367.568)
Kidney dysfunction 11 221.896 (107.470 to 386.146)
polycythemia 8 246.421 (169.398 to 367.568)
Hyperlipidemia 1 214.296
Adult still disease 1 249.905
Differences between two groups were performed with Mann–Whitney U-test for nonpIL-37 and several useful markers of the disease activity
such as BASDAI, CRP and ESR. These results consisted
with our published data that inflammatory reaction stimu-
lates IL-37 production [16,30]. Taken together, our result
implies that AS inflammatory reaction and their inflam-
matory cytokines might play a positive feedback to induce
the expression of IL-37 during the complication develop-
ment of AS.
Although the mechanism of pathogenesis in AS is
poorly understood, the published data have indicated that
pro-inflammatory cytokines play an important role in the
inflammatory development in AS [6-12]. Previous studies
demonstrated that serum levels of TNF, IL-6, IL-23 andof AS clinical characteristics
e) n Absent median (interquartile range) P-value
22 193.888 (93.536 to 294.802) 0.0263
38 214.052 (93.536 to 386.146) ns
29 213.832 (93.536 to 386.146) ns
45 218.356 (93.536 to 386.146) ns
39 212.152 (93.536 to 386.146) ns
35 216.685 (93.536 to 341.248) ns
38 213.114 (93.536 to 386.146) ns
45 218.012 (93.536 to 386.146) ns
45 214.193 (93.536 to 367.568) ns
arametric data. P < 0.05 represents a significant difference. NS. Not significant.
Figure 4 Elevated IL-37 mRNA and protein levels in AS patients with osteoporosis and complications. The expressions of IL-37 mRNAs in
PBMCs (A) and IL-37 protein levels in serum (B) were measured in AS patients with OP (n = 24) and without OP (n = 22), as well as HC (n = 35).
Results are expressed as mean ± SEM (A) Each individual is expressed as an symbol; horizontal lines indicate median values (B). OP, osteoporosis;
HC, healthy control; NS, not significant; *P < 0.05; **P < 0.01.
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ing these pro-inflammatory cytokines with antibodies or
recombinant soluble receptor dramatically alleviated axial
and peripheral inflammation in AS [13-15]. In this study,
we observed the higher serum levels of these cytokines in
AS than that in HC (data not shown). More importantly,
we also found that the elevating levels of IL-37 in serumFigure 5 Recombinant IL-37 decreases pro-inflammatory cytokines pr
and HC (n = 35) were stimulated with or without IL-37 (100 ng/ml) for 6 h,
extracted and analyzed for TNF-α (A), IL-6 (B) IL-23 (C) and IL-17 (D) mRNA
stimulated with or without IL-37 (100 ng/ml) for 24 h and then incubated
examined for TNF-α (E), IL-6 (F), IL-23 (G) and IL-17 (H) protein levels using
significant difference. AS + IL-37, PBMCs from AS stimulated with the recom
IL-37; NS, not significant; *P < 0.05; **P < 0.01.and PBMCs from patients with AS compared to HC.
Spearman correlation test analysis also showed that serum
IL-37 levels were positively correlated with major pro-
inflammatory cytokines such as TNF, IL-6 and IL-17 in AS.
It has been demonstrated that the IL-37 mRNA and pro-
tein expression can be induced by TNF-α via activa-
tion of nuclear factor(NF)-kB and activator protein (AP)-1oductions in PBMCs of AS patients. PBMCs from AS patients (n = 46)
cells then cultured with LPS (1 ug/ml) for 4 h, the total RNAs were
s by RT-PCR. PBMCs from AS patients (n = 46) and HC (n = 35) were
further with LPS (1 μg/ml) for 8 h, supernatants of the cells were
ELISA. Results are expressed as mean ± SEM, P < 0.05 represents a
binant IL-37; HC + 37, PBMCs from HC stimulated with the recombinant
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larly, TNF-α also induce IL-37 expression in PBMCs from
healthy controls [22], indicating TNF-α as one of inducers
involved in the up-regulation of IL-37 in AS. Not only
that, using anti-TNF-α antibody reduces the levels of IL-6
and Th17 responses, which reflects that IL-6 and other
cytokines serve as an important downstream effectors
of TNF-α pathway [14,39]. Thus, we speculate that
inflammation signaling caused by TNF-α signal path-
way not only exacerbated the inflammatory response
in pathogenesis of AS but also promoted the expression
of anti-inflammatory cytokine IL-37 to limit excessive in-
flammation in AS. However, further studies are needed to
define the direct or indirect role of these cytokines in
driving IL-37 expression.
In recent reports, IL-37 was shown to be a negative me-
diator to reduce pro-inflammatory cytokine productions
in inflammatory diseases [24,25]. To further explore the
effects of IL-37 on the pro-inflammatory cytokines that
are responsible for the pathogenesis of AS, the recombin-
ant human IL-37 protein was used to stimulate PBMCs
from AS patients and HC. In our study, we showed the
recombinant IL-37 proteins remarkably attenuate LPS-
induced TNF-α, IL-6, IL-17, IL-23 expressions in PBMCs
from AS patients but not in HCs. Although the inhi-
bitions of pro-inflammatory cytokine expression signaling
pathways by IL-37 remain to elusive, Nold et al. re-
vealed that IL-37 can reduce the expression of STAT3
[22], while the STAT3 have been reported to closely re-
lated to AS [40,41]. We suspect that IL-37 may through
regulate several critical signal transducers like STAT3
to attenuates the pro-inflammatory cytokines produc-
tions which may be able to improve inflammatory re-
actions of AS.
The findings of our study provide a new insight for
unraveling the intriguing balance between IL-37 and the
pro-inflammatory cytokines in AS. However, further stud-
ies are needed to determine the regulatory mechanism of
IL-37 in pathogenesis of AS.
Conclusions
Altogether, we highlighted that the levels of IL-37 are in-
creased in AS patients, and it is associated with the pro-
inflammatory cytokines, disease activity and complications.
We also demonstrated that IL-37 can effectively alleviate
the expressions of pro-inflammatory cytokines (TNF-α,
IL-6, IL-17 and IL-23) that are responsible for the patho-
genic development of AS. Hence, our study implied that
the inflammatory reactions and their inflammatory cyto-
kines in AS enhance the expression of IL-37, but IL-37 act
as a negative regulator to smother the excessive inflamma-
tion, thereby protecting against OP in AS. This study
might offer a new target (IL-37) for AS therapy. Further
researches are necessary to identify the mechanisms andsignal pathways for IL-37 functions and expression regula-
tions in the pathogenesis of AS.
Additional file
Additional file 1: Figure S1. IL-37 protein levels in active and inactive
AS patients with or without OP as well as HC. (A) IL-37 protein levels in
serum were measured in active (n = 7) and inactive (n = 15) AS patients
without OP as well as HC (n = 35). (B) IL-37 protein levels in serum were
measured in active (n = 18) and inactive (n = 6) AS patients with OP as
well as HC (n = 35). Results are expressed as mean ± SEM. Each individual
is expressed as an symbol; horizontal lines indicate median values. OP,
osteoporosis; HC, healthy control; NS, not significant; *P < 0.05; **P < 0.01.
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aminotransferase.
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